Dyne Readies DMD Exon-Skipper For Filing, Could Be Competitive With Sarepta Drug

BLA Filing Planned For Q2 2026

Dyne's DMD drug performed better than placebo across six functional measures (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D